CytomX Therapeutics (CTMX) Stock News

CytomX Therapeutics (Nasdaq: CTMX) announced that the U.S. FDA has granted Fast Track Designation (FTD) to varsetatug masetecan (Varseta-M) for the treatment of patients with relapsed/refractory metastatic colorectal cancer (R/R mCRC). The designation follows previously reported encouraging Phase 1 data in this setting.

Varseta-M (CX-2051) is a potential first-in-class, masked, conditionally activated antibody-drug conjugate directed at EpCAM and armed with a topoisomerase-1 inhibitor payload. CytomX plans to initiate a potential Varseta-M monotherapy registrational study in R/R mCRC in the first half of 2027. The company’s broader pipeline includes CX-801, a masked interferon alpha-2b PROBODY cytokine initially in development for metastatic melanoma, and it maintains collaborations with Amgen, Regeneron and Moderna.

CytomX Therapeutics (Nasdaq: CTMX) reported Q2 2026 revenue of $1.4 million, down from $18.7 million a year earlier, and a net loss attributable to common stockholders of $20.7 million versus $0.2 million. Operating expenses rose to $25.2 million, driven mainly by higher Varseta-M manufacturing, R&D personnel, and G&A costs.

CytomX ended the quarter with $330.3 million in cash, cash equivalents and investments, excluding a subsequent $37.0 million payment from Regeneron, and projects cash runway to at least 2H 2028. The Regeneron collaboration expansion now covers up to approximately $4.0 billion in potential milestones.

Varsetatug masetecan (Varseta-M, CX-2051) completed Phase 1 CRC monotherapy enrollment (113 patients), with a data update expected by end-2026 and a registrational study targeted for 1H 2027. New CRC combination and non-CRC expansion studies are scheduled from Q3–Q4 2026. CX-801 Phase 1 in melanoma is progressing in monotherapy and KEYTRUDA® combinations, with initial combo data expected in 1H 2027.

CytomX Therapeutics (Nasdaq: CTMX) has appointed Alejandra Carvajal as Chief Legal Officer, where she will support strategic, operational and pipeline initiatives. According to CytomX, she brings over 20 years of legal experience guiding biotechnology companies through transformational change and has held senior legal roles at Mersana, Momenta, Cerulean and Millennium.

CytomX highlights her involvement in prior corporate transactions, including Mersana’s sale to Day One Biopharmaceuticals and Momenta’s acquisition by Johnson & Johnson. The company reiterates its focus on its PROBODY® therapeutic platform and clinical-stage assets varsetatug masetecan (Varseta-M; CX-2051) for metastatic colorectal cancer and CX-801 for metastatic melanoma.

CytomX Therapeutics (Nasdaq: CTMX) will report its second quarter 2026 financial results on Thursday, August 6, 2026, after the close of U.S. markets. The company will host a conference call and webcast at 5:00 p.m. ET / 2:00 p.m. PT, accessible via the Events and Presentations page of its investor relations website, with advance registration recommended.

CytomX is a clinical-stage, oncology-focused biopharmaceutical company developing masked, conditionally activated PROBODY therapeutics. Its clinical pipeline includes varsetatug masetecan (Varseta-M; CX-2051), a masked ADC targeting EpCAM for metastatic colorectal cancer, and CX-801, a masked interferon alpha-2b PROBODY cytokine initially for metastatic melanoma. The company also maintains strategic collaborations with Amgen, Regeneron and Moderna.

CytomX Therapeutics (Nasdaq: CTMX) has appointed Charles Fuchs, M.D., M.P.H., a board-certified medical oncologist with over three decades of oncology leadership, to its Board of Directors. Fuchs most recently served as Chief Medical Officer of Tubulis and previously led global oncology and hematology drug development at Genentech and Roche, where he oversaw approvals for therapies including Lunsumio, Columvi, Polivy and Tecentriq.

According to CytomX, his expertise in gastrointestinal oncology is expected to support advancement of varsetatug masetecan (Varseta-M; CX-2051), an EpCAM-directed antibody-drug conjugate for metastatic colorectal cancer, and CX-801, a masked interferon alpha-2b PROBODY cytokine initially in development for metastatic melanoma.

CytomX (NASDAQ: CTMX) expanded its strategic research and licensing collaboration with Regeneron to develop conditionally activated bispecific cancer therapies using PROBODY and Veloci-Bi platforms.

CytomX will receive a $37 million target nomination payment, with total potential milestones of up to approximately $4 billion and tiered royalties, while Regeneron funds preclinical, clinical and commercialization activities.

CytomX Therapeutics (Nasdaq: CTMX) announced management participation in two June 2026 investor conferences. Events include fireside chats and one-on-one investor meetings.

Jefferies Global Healthcare Conference: June 4, 2026, 3:10 p.m. ET, New York, NY. Goldman Sachs 47th Annual Global Healthcare Conference: June 10, 2026, 9:20 a.m. ET, Miami, FL. Live webcasts will be available on CytomX’s website.

CytomX Therapeutics (Nasdaq: CTMX) appointed Mamata Gokhale, Ph.D., RAC as Senior Vice President of Regulatory Affairs, effective May 18, 2026. She will lead global regulatory strategy and interactions to advance CytomX’s PROBODY pipeline, including lead program Varseta-M, toward clinical development milestones and potential commercialization.

CytomX Therapeutics (Nasdaq: CTMX) reported Q1 2026 results and a business update on May 7, 2026. Cash, cash equivalents and investments were $346.7 million with runway to at least H2 2028 after a $250 million March follow-on offering. Total revenue was $10.3 million versus $50.9 million in Q1 2025. Varsetatug masetecan (Varseta-M) completed enrollment of 40 patients in dose optimization (8.6 and 10 mg/kg Q3W); additional data expected in H2 2026 to inform monotherapy dose and potential registrational trial targeting 1H 2027. Multiple combination and expansion studies are planned through 2027. CX-801 development and collaborations with Amgen, Regeneron, and Moderna continue.